Evercore ISI disclosed Organovo Holdings Inc (NASDAQ:ONVO), hiking its price target to $4.50 earlier today
- Updated: November 28, 2016
Yesterday Organovo Holdings Inc (NASDAQ:ONVO) traded -4.86% lower at $3.13. The company’s 50-day moving average is $3.16 and its 200-day moving average is $3.54. The last closing price is down -11.70% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 895,349 shares of the stock were exchanged, down from an average trading volume of 1,035,090
Stating a potential upside of 0.44%, Evercore ISI bumped up the target of Organovo Holdings Inc (NASDAQ:ONVO) to $4.50
Previously on 11/09/2016, Zacks Investment Research reported on Organovo Holdings Inc (NASDAQ:ONVO) increased the target price from $0.00 to $3.25. At the time, this indicated a possible upside of 0.15%.
See Chart Below
Organovo Holdings Inc has a 52 week low of $1.60 and a 52 week high of $4.99 The company’s market cap is currently $0.
About Organovo Holdings Inc (NASDAQ:ONVO)
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.